title: Hyperzincuria and hypozincemia in patients treated with cisplatin.
abstract: The effect of cis-diamminedichloroplatinum (DDP) on plasma and urinary zinc was studied in fifteen patients with squamous cell carcinoma. A decrease in plasma zinc accompanied by an increase in urinary zinc excretion was observed. Pretreatment plasma or urinary zinc did not correlate with tumor size or site, nor was there a correlation between changes in these measurements and a response to therapy. The enhanced excretion of urinary zinc may be related to a decrease in amino acid resorption in the proximal tubule. It is concluded that DDP administration may result in hyperzincuria and could potentially precipitate a symptomatic zinc deficiency state.
authors.affiliation: Division of Oncology, Veterans Administration Medical Center, Buffalo, New York.
authors.forename: J D
authors.initials: JD
authors.lastname: Sweeney
authors.forename: P
authors.initials: P
authors.lastname: Ziegler
authors.forename: C
authors.initials: C
authors.lastname: Pruet
authors.forename: M B
authors.initials: MB
authors.lastname: Spaulding
mesh_terms: D002294:Carcinoma, Squamous Cell / Q000097:blood / Q000188:drug therapy / Q000652:urine; D002940:Circadian Rhythm; D002945:Cisplatin / Q000627:therapeutic use*; D006801:Humans; D008297:Male; D015032:Zinc / Q000097:blood* / Q000652:urine*
chemical_list: D015032:Zinc; D002945:Cisplatin